title: Phosphodiesterase-IV inhibition, respiratory muscle relaxation and bronchodilation by WAY-PDA-641.
abstract: The ability of 1-[3-(cyclopentyloxy)-4-methoxyphenyl]ethanone (E)-O-(aminocarbonyl) oxime) (WAY-PDA-641) to inhibit cyclic AMP-metabolizing phosphodiesterases (PDEs) and to relax respiratory muscle was explored as part of a program to identify a PDE-IV inhibitor for potential use in the treatment of asthma. WAY-PDA-641 was identified as a preferential inhibitor of PDE-IV, possessing 36 times greater potency versus canine trachealis PDE-IV than PDE-III (IC50, 4.2 x 10(-7) M and 1.5 x 10(-5) M, respectively). The classification of WAY-PDA-641 as a preferential PDE-IV inhibitor was supported in radioligand binding studies, which demonstrated that 10 microM WAY-PDA-641 did not displace ligands from a large number of receptors, and in functional studies, which used isolated guinea pig tracheal rings. Under conditions in which tracheal rings were made sensitive to the relaxant effects of PDE-IV or PDE-III inhibitors, WAY-PDA-641 induced relaxation with IC50S of 2.6 x 10(-8) M (PDE-IV) and 3.2 x 10(-5) M (PDE-III). Moreover, PDE-IV inhibitory concentrations of WAY-PDA-641 significantly potentiated the relaxant effects of albuterol. WAY-PDA-641 reversed tracheal contractions induced by prostaglandin F2 alpha, leukotriene D4 or histamine in a biphasic manner consistent with its activity as a preferential PDE-IV inhibitor. The IC50S for reversal of each spasmogen were similar, which confirmed that WAY-PDA-641 is a functional antagonist of respiratory muscle contraction.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Division of Inflammation/Bone Metabolism, Wyeth-Ayerst Research, Princeton, New Jersey.
authors.forename: R J
authors.initials: RJ
authors.lastname: Heaslip
authors.forename: L J
authors.initials: LJ
authors.lastname: Lombardo
authors.forename: J M
authors.initials: JM
authors.lastname: Golankiewicz
authors.forename: B A
authors.initials: BA
authors.lastname: Ilsemann
authors.forename: D Y
authors.initials: DY
authors.lastname: Evans
authors.forename: B D
authors.initials: BD
authors.lastname: Sickels
authors.forename: J K
authors.initials: JK
authors.lastname: Mudrick
authors.forename: J
authors.initials: J
authors.lastname: Bagli
authors.forename: B M
authors.initials: BM
authors.lastname: Weichman
mesh_terms: D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000037:antagonists & inhibitors*; D000420:Albuterol / Q000494:pharmacology; D000818:Animals; D001993:Bronchodilator Agents / Q000494:pharmacology*; D004285:Dogs; D006168:Guinea Pigs; D066298:In Vitro Techniques; D007527:Isoenzymes / Q000037:antagonists & inhibitors*; D008297:Male; D010091:Oximes / Q000494:pharmacology*; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology*; D012132:Respiratory Muscles / Q000187:drug effects* / Q000502:physiology; D012701:Serotonin / Q000494:pharmacology; D014132:Trachea / Q000187:drug effects / Q000502:physiology
chemical_list: D001993:Bronchodilator Agents; D007527:Isoenzymes; D010091:Oximes; D010726:Phosphodiesterase Inhibitors; D012701:Serotonin; C085988:filaminast; D015105:3',5'-Cyclic-AMP Phosphodiesterases; D000420:Albuterol